- Open
- 1.02
- High
- 1.10
- Low
- 0.95
- Close
- 0.97
- Change
- -0.07 (-7.32%)
- Volume
- 6,956,928
| 15 Oct 2026 | 07:00:07 | Update on Launch of Lung Cancer Test in USA |
| 30 Sept 2026 | 07:00:06 | Interim Results |
| 3 Aug 2026 | 13:00:00 | Laboratory Expansion to Accelerate Sales in USA |
| 22 Jul 2026 | 12:00:00 | Update on Sales in USA |
| 28 May 2026 | Annual Report and Accounts to 31 December 2025 | |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Sep 2025 | Financial Statements for the year ended 31 December 2024 |
Cizzle Biotechnology Holdings PLC develops diagnostic tests for early cancer detection, focusing on lung cancer. The company has created a non-invasive blood test based on the CIZ1B biomarker, which is associated with early-stage lung cancer. Cizzle generates revenue through commercial royalty-bearing arrangements to license its technology and collaborates with cancer care centers. It operates primarily in the UK and aims to improve early cancer diagnosis through its proprietary testing methods.
| 15 Oct 2026 | 07:00:07 | Update on Launch of Lung Cancer Test in USA |
| 30 Sept 2026 | 07:00:06 | Interim Results |
| 3 Aug 2026 | 13:00:00 | Laboratory Expansion to Accelerate Sales in USA |
| 22 Jul 2026 | 12:00:00 | Update on Sales in USA |
| 28 May 2026 | Annual Report and Accounts to 31 December 2025 | |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Sep 2025 | Financial Statements for the year ended 31 December 2024 |
Cizzle Biotechnology Holdings PLC develops diagnostic tests for early cancer detection, focusing on lung cancer. The company has created a non-invasive blood test based on the CIZ1B biomarker, which is associated with early-stage lung cancer. Cizzle generates revenue through commercial royalty-bearing arrangements to license its technology and collaborates with cancer care centers. It operates primarily in the UK and aims to improve early cancer diagnosis through its proprietary testing methods.
| 15 Jul 2026 |
| 07:00:05 |
| Half Year Operational Update |
| 5 Aug 2026 |
| Cizzle Biotechnology begins US commercial launch of lung cancer blood test |
| 15 Jul 2026 | Cizzle Biotechnology reports US accreditation and patent progress in H1 2026 |
| 12 Jun 2026 | Week Ahead: Tesco set to steal headlines |
| 12 Jun 2026 | Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test |
| 21 May 2026 | Cizzle Biotechnology sets date for Annual General Meeting |
| 20 May 2026 | Cizzle Biotechnology targets early lung cancer detection market |
| 15 Jul 2026 |
| 07:00:05 |
| Half Year Operational Update |
| 5 Aug 2026 |
| Cizzle Biotechnology begins US commercial launch of lung cancer blood test |
| 15 Jul 2026 | Cizzle Biotechnology reports US accreditation and patent progress in H1 2026 |
| 12 Jun 2026 | Week Ahead: Tesco set to steal headlines |
| 12 Jun 2026 | Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test |
| 21 May 2026 | Cizzle Biotechnology sets date for Annual General Meeting |
| 20 May 2026 | Cizzle Biotechnology targets early lung cancer detection market |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £21m | +0.4% | |
| £11m | +0.0% | |
| £11m | +1.8% | |
| £10m | -0.2% | |
CIZCizzle Biotechnology Holdings PLC | £4m | -0.3% |
| £2m | -0.7% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £21m | +0.4% | |
| £11m | +0.0% | |
| £11m | +1.8% | |
| £10m | -0.2% | |
CIZCizzle Biotechnology Holdings PLC | £4m | -0.3% |
| £2m | -0.7% |
